PATIENT ORIENTED RESEARCH IN CUTANEOUS ONCOLOGY

这是Stuart R. Lessin医学博士获得的面向患者的研究（POR）申请（K24）的职业中期研究者奖，将专注于皮肤肿瘤学。Lessin博士是宾夕法尼亚大学皮肤科皮肤淋巴瘤项目的副教授和联合主任。他高度致力于POR，并在皮肤t细胞淋巴瘤（CTCL）领域拥有良好的记录（资助和发表）。他开发了基于t细胞受体（TCR）基因表达的淋巴增生性皮肤病分子诊断技术，并将其转化为利用TCR作为靶点的新治疗策略。Lessin博士目前是FDA资助的一项I期临床试验的首席研究员，该试验测试了CTCL患者中人类TCR遗传（DNA）疫苗接种的安全性和有效性。本提案的总体研究目标将是开发和测试利用治疗性DNA疫苗、肽疫苗和拟肽剂技术治疗皮肤癌的新方法。Lessin博士一直积极参与指导和培训贫困地区各级受训者——医科学生、住院医生/研究员和初级教员。这是通过一系列完善的扶贫项目实现的。目前，Lessin博士在皮肤科的皮肤肿瘤学奖学金项目、NIH培训补助金（T32）、药物研究单元、皮肤病800研究选修课和青年教师导师项目中担任导师。宾夕法尼亚大学的承诺和能力，提供必要的机会和设施的贫困是非凡的。一个完善的POR培训核心课程，一个由NIH赞助的普通临床研究中心（GCRC），以及基础和临床研究人员之间的杰出互动，提供了一个独特而充满活力的环境来指导和培训POR个人。莱辛博士将参加扶贫中心核心课程和GCRC。该奖项将为莱辛博士提供关键的基础设施，以开展贫困研究并指导其他研究人员开展贫困研究。承诺付出50%的努力将确保新疗法的临床试验继续获得资金和保护时间。此外，它将使Lessin博士能够继续参与正在进行的部门和机构POR项目，并作为宾夕法尼亚大学POR年轻研究人员的榜样和导师。

This is a Midcareer Investigator Award in Patient-Oriented Research (POR) application (K24) for Stuart R. Lessin, M.D and will focus on cutaneous oncology. Dr. Lessin is Associate Professor and Co-Director of the Cutaneous Lymphoma Program in the Department of Dermatology at the University of Pennsylvania. He is highly committed to POR and has a well established track record (funding and publications) in the area of cutaneous T-cell lymphoma (CTCL). He has developed techniques for the molecular diagnosis of lymphoproliferative skin diseases based on T-cell receptor (TCR) gene expression and translated them into new strategies of therapy utilizing the TCR as a target. Dr. Lessin is currently the principal investigator of a FDA funded Phase I clinical trial testing the safety and efficacy of genetic (DNA) vaccination of human TCR in patients with CTCL. The overall research goal of this proposal will be to develop and test novel therapeutic approaches to skin cancers utilizing the technologies of therapeutic DNA vaccines, peptide vaccines and peptidomimetics. Dr. Lessin has been heavily involved in the mentoring and training of trainees in POR at all levels - medical students, residents/fellows and junior faculty. This has been accomplished through a series of well established POR programs. Currently, Dr. Lessin serves as a mentor in the Department of Dermatology's Cutaneous Oncology Fellowship Program, NIH Training Grant (T32), Drug Study Unit, Derm 800 Research elective and Junior Faculty Mentor's Program. The University of Pennsylvania's commitment and ability to provide opportunities and facilities necessary for POR is extraordinary. A well established Core Curriculum in POR Training, a NIH sponsored General Clinical Research Center (GCRC) and outstanding interaction between basic and clinical investigators provides a unique and dynamic environment in which to conduct and train individuals in POR. Dr. Lessin will participate in the POR core curriculum and the GCRC. This award will provide a critical infrastructure for Dr. Lessin to pursue POR and to mentor other investigators in POR. A commitment of 50 percent effort will ensure the continued acquisition of funding and protected time for clinical testing of new therapies. Furthermore, it will enable Dr. Lessin to continue to participate in the ongoing departmental and institutional POR programs and serve as a role model and mentor for young investigators in POR at the University of Pennsylvania.